Enanta's RSV treatment misses main goal in mid-stage study

Enanta Pharmaceuticals

29/09/2025 11:43

Sept 29 (Reuters) - Enanta Pharmaceuticals ENTA.O said on Monday its treatment for respiratory syncytial virus failed to shorten the time taken to reduce the severity of some symptoms, missing the primary goal of a mid-stage study.

Shares of the company were down nearly 30% in premarket trading.

 (Reporting by Puyaan Singh in Bengaluru; Editing by Krishna Chandra Eluri)

 ((Puyaan.Singh@thomsonreuters.com;))